That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

Vijay Iyengar Biography and Net Worth

EVP of Incyte

Vijay Iyengar joined Incyte in May 2016 as Executive Vice President, Global Strategy and Corporate Development leading the company’s Global Product Strategy, Business Development and Licensing, and Alliance Management teams. Dr. Iyengar has more than 13 years of pharmaceutical industry experience, most recently serving as the President of Genoptix Corporation, a Novartis Company. At Genoptix, he led a 650-person organization focused on delivering CAP/CLIA certified oncology diagnostic testing as well as providing clinical trial assay development and execution services. Previously, Dr. Iyengar held leadership roles in both U.S. and Global commercial functions at Novartis—he was Vice President and Rare Diseases Franchise Head at Novartis Oncology and Vice President and Oncology General Manager of Novartis Greece. Before joining Novartis in 2003, Dr. Iyengar was an Engagement Manager at McKinsey & Company where he served pharmaceutical and medical device clients as part of their healthcare practice. Dr. Iyengar received his Bachelor of Science degree in Biology from Stanford University and earned his MD from Harvard Medical School.

What is Vijay K. Iyengar's net worth?: The estimated net worth of Vijay K. Iyengar is at least $2.57 million as of July 25th, 2024. Dr. Iyengar owns 36,701 shares of Incyte stock worth more than $2,569,070 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Iyengar may own. Learn More about Vijay K. Iyengar's net worth.
How do I contact Vijay K. Iyengar?: The corporate mailing address for Dr. Iyengar and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Vijay K. Iyengar's contact information.
Has Vijay K. Iyengar been buying or selling shares of Incyte?: Vijay K. Iyengar has not been actively trading shares of Incyte during the last ninety days. Most recently, Vijay K. Iyengar sold 15,571 shares of the business's stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $70.00, for a transaction totalling $1,089,970.00. Following the completion of the sale, the executive vice president now directly owns 36,701 shares of the company's stock, valued at $2,569,070. Learn More on Vijay K. Iyengar's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (CEO & Chairman), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 58,851 shares worth more than $3,787,827.45. The most recent insider tranaction occured on November, 6th when EVP Barry P Flannelly sold 3,680 shares worth more than $293,222.40. Insiders at Incyte own 17.6% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 11/6/2024.

Vijay K. Iyengar Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/25/2024	Sell	15,571	$70.00	$1,089,970.00	36,701
1/2/2024	Sell	657	$65.00	$42,705.00	43,412
1/26/2023	Sell	7,000	$85.00	$595,000.00	42,835
12/23/2022	Sell	17,324	$80.80	$1,399,779.20	37,855
7/7/2022	Sell	5,787	$79.38	$459,372.06	40,313
7/29/2021	Sell	4,911	$78.29	$384,482.19
7/9/2018	Sell	606	$71.34	$43,232.04
1/2/2018	Sell	5,000	$97.26	$486,300.00

Vijay K. Iyengar Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $70.00

$69.88

$71.33

50 Day Range

MA: $69.59

$63.22

$83.38

2 Week Range

Now: $70.00

$50.35

$83.95

Volume

331,554 shs

Average Volume

2,368,572 shs

Market Capitalization

$13.49 billion

P/E Ratio

500.04

Dividend Yield

N/A

Beta

0.71

Breaking News: Tesla headed to $500…

From WealthPress | Ad